Cambridge Healthtech Institute’s 4th Annual

Adoptive T Cell Therapy

Delivering CAR, TCR, and TIL from Research to Reality
August 29 - 30, 2017 | Sheraton Boston | Boston, MA

Greater understanding of T cell biology as well as promising patient outcomes have led to immunotherapies accelerating at an unprecedented pace. With multiple engineered receptors making an impact, many biotech and pharma companies are already entering clinical trials in a race to get to market. However, with the end goal being the same – improved patient outcomes – there is still work to be done. Cambridge Healthtech Institute’s Fourth Annual Adoptive T Cell Therapy event will focus on the steps needed to deliver CAR, TCR, and TIL therapies to the patient by examining emerging science, autologous immune cell products, and allogenic immune cell products. Overall, this event will address clinical progress, case studies, and critical components to make adoptive T cell therapy work.

Preliminary Agenda


WHAT’S NEW IN ADOPTIVE CELL THERAPY

Building Better T Cell Therapies: The Power of Molecular Profiling

Mark Bonyhadi, Ph.D., Vice President, Research, Juno Therapeutics

Tricked Out CARs, the Next Generation of CAR T Cells

Richard Morgan, Ph.D., Vice President, Immunotherapy, Bluebird Bio

Development of Axicabtagene Ciloleucel: A Translational Perspective

Adrian Bot, M.D., Ph.D., CSO, Kite Pharma

 

ADOPTIVE CELL THERAPY USING NON-GENETICALLY MANIPULATED LYMPHOCYTES

The End Game: Adjuvant γδ T Cell-Based Strategies for Consolidation and Eradication of Residual Cancer

Lawrence S. Lamb, Jr., M.N., Ph.D., Professor, Medicine; Director, Cell Therapy Laboratory, University of Alabama at Birmingham

Personalized Adoptive Cell Therapy Using Novel XPRESIDENT® Derived Targets

Steffen Walter, Ph.D., CSO, Immatics US, Inc.


ADOPTIVE CELL THERAPY USING CHIMERIC ANTIGEN RECEPTORS (CAR) AND T CELL RECEPTORS (TCR)

Immunotherapy for Ovarian Cancer: One Cell at a Time

Wendy J. Fantl, Ph.D., Assistant Professor, Obstetrics and Gynecology, Stanford University School of Medicine

Engineering the Future of Cellular Therapy: Current Perspectives and Future Directions

Matt Frigault, M.D., Post-Doctoral Fellow, Cellular Immunotherapy, Dana-Farber Cancer Institute

Chairperson’s Remarks

Richard Morgan, Ph.D., Vice President, Immunotherapy, Bluebird Bio

SPEAR T Cells for Solid Tumor Therapy

Mark Dudley, Ph.D., Senior Vice President, Bioprocessing, Adaptimmune

IMPACT Fusion Proteins Redirect CAR19 T Cell Cytotoxicity to Diverse Tumor Antigens

Paul Rennert, Ph.D., President and CSO, Aleta Biotherapeutics Inc.

Advancement from Boutique to Global in the 20th Year of Chimeric Antigen Receptor T Cell Trials

Bruce Levine, Ph.D., Barbara and Edward Netter Professor, Cancer Gene Therapy, University of Pennsylvania Perelman School of Medicine


ALLOGENEIC IMMUNE CELL PRODUCTS

TALEN Gene Editing for “Off-the-Shelf” Allogeneic CAR T-Cell Products

Julianne Smith, Ph.D., Vice President, Translational Science,

Cytotherapy with Targeted Allogenic NK Cells

Hans Klingemann, M.D., Ph.D., Vice President, Research & Development, NantKwest, Inc.




For more details on the conference, please contact:
Samantha Drinkwater
Senior Conference Director
Cambridge Healthtech Institute
781.972.5461
sdrinkwater@healthtech.com

For exhibit & sponsorship opportunities, please contact: 

Rod Eymael
Manager, Business Development
781-247-6286
reymael@healthtech.com

YouTubeOutlookYouTubeLinkedInTwitter #IOSummit  

Japan-Flag   Korea-Flag   China-Simplified-Flag   China-Traditional-Flag

Register Today